Navigation Links
Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/19/2008

PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that it has cancelled its corporate presentation planned for today at the Lazard Capital Markets 5th Annual Healthcare Conference due to the proximity of the release of preliminary top-line data from the first Phase III pivotal clinical trial of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

The company anticipates that it will release the preliminary top-line data within the next week.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains a forward-looking statement related to the timing of the release of clinical results related to Jazz Pharmaceuticals' JZP-6 product candidate for the treatment of fibromyalgia. This forward-looking statement is based on the company's current expectations and inherently involves significant risks and uncertainties. The actual timing of the release of clinical results could differ from that anticipated in such forward-looking statement as a result of these risks and uncertainties. Risk factors related to Jazz Pharmaceuticals' clinical trials are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 14, 2008.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MiddleBrook Pharmaceuticals Hires Key Commercial Team Members
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical imaging research scientist at ... been selected as this year’s recipients of two top awards from SPIE, the ... with other honorees to accept their awards at a banquet in San Diego, California, ...
(Date:6/23/2017)... IN (PRWEB) , ... June 23, 2017 , ... ... voice for model aircraft flying hobbyists, and the University Aviation Association (UAA), the ... college students. The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. ... Timothy Reinhardt to manage the new site. , Tim has 25 years of ... most recent role as the Director of Manufacturing and Supplier Quality Assessment. ...
(Date:6/22/2017)... ... 2017 , ... AESKU.GROUP, an innovation leader in autoimmune ... GmbH, thereby expanding its product portfolio to include allergy and food intolerance diagnostics. ... eczema or a food allergy. Allergies are escalating to epidemic proportions and becoming ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):